Clinical Outcomes for Patients with Acute Myeloid Leukemia Harboring IDH1 Mutation After Intensive Chemotherapy | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 128, Volume 88, Issue 1, July 2022, Pages 3089-3093 PDF (475.23 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2022.244546 | ||
| Authors | ||
| Nour El Hoda H. Ab* ; Mohamed O. Azzazi; Walaa A. El Salakawy; John A. Saweris | ||
| Abstract | ||
| Background: Acute myeloid leukemia (AML) is heterogeneous myeloid disorder with multifactorial pathogenic mechanisms and a broad range of prognosis. AML is characterized by clonal proliferation of poorly differentiated cells of the myeloid lineage. Objective: This study aimed to detect Isocitrate Dehydrogenase 1 (IDH1) mutation in adult Egyptian AML patients and to find correlation between the mutation and prognosis & survival in those patients after intensive chemotherapy. Patients and Methods: Our study included 98 subjects with newly diagnosed AML. They all presented to Ain Shams University Hospital (Hematology Unit). All Patients included in the study were subjected to: History taking and clinical examination, laboratory investigations including routine investigations and cytogenetic studies for detection of IDH 1 mutation. All patients were followed up for their response to treatment for a period of 6 months. Results: IDH1 mutation occurs in a considerable percentage of Egyptian AML patients that shows independent bad prognostic impact on the clinical outcome. Conclusion: IDH1 mutation occurred in a considerable percentage of Egyptian AML patients that showed independent bad prognostic impact on the clinical outcome. | ||
| Keywords | ||
| Myeloid leukemia; IDH1 mutation; Intensive chemotherapy | ||
|
Statistics Article View: 160 PDF Download: 392 |
||
